Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 1/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375567 | 1.00 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| SCHEMBL16602137 | 1.00 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| SCHEMBL29373547 | 1.00 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| Bromide SCHEMBL3276906 | 0.99 | DRD2 (0.97) | DRD2DRD4MEN1ABL1ALPL | |
| SCHEMBL16281797 | 0.89 | DRD2 (0.80) | DRD2DRD4MEN1ABL1ALPL | |
| SCHEMBL13686544 | 0.89 | DRD2 (0.80) | DRD2DRD4MEN1ABL1ALPL | |
| (-)-Higenamine SCHEMBL5898911 | 0.88 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| Higenamine SCHEMBL636788 | 0.88 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| (+)-Higenamine SCHEMBL5898913 | 0.88 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL | |
| Higenamine SCHEMBL30105922 | 0.88 | DRD2 (1.00) | DRD2DRD4MEN1ABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615963-A1 | GENETICALLY MODIFIED BENZYLISOQUINOLINE ALKALOID-PRODUCING HOST CELLS WITH MODIFIED EFFLUX TRANSPORTER GENE EXPRESSION | River Stone Biotech ApS (DK) | 2025-09-17 | — | — | EP | claimed |
| US-20240209403-A1 | METHODS OF PRODUCING MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-06-27 | — | — | US | claimed |
| US-12018304-B2 | Benzylisoquinoline alkaloid (BIA) precursor producing microbes, and methods of making and using the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-25 | — | — | US | claimed |
| WO-2024100063-A1 | GENETICALLY MODIFIED BENZYLISOQUINOLINE ALKALOID-PRODUCING HOST CELLS WITH MODIFIED EFFLUX TRANSPORTER GENE EXPRESSION | RIVER STONE BIOTECH APS (DK) | 2024-05-16 | — | — | WO | claimed |
| US-20240150805-A1 | Glycosylated Opioids | RIVER STONE BIOTECH APS (DK) | 2024-05-09 | — | — | US | claimed |
| EP-4334441-A1 | GLYCOSYLATED OPIOIDS | River Stone Biotech ApS (DK) | 2024-03-13 | — | — | EP | claimed |
| US-11884949-B2 | Methods of producing morphinan alkaloids and derivatives | ANTHEIA, INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-20230332195-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING BENZYLISOQUINOLINE ALKALOIDS | RIVER STONE BIOTECH APS (DK) | 2023-10-19 | — | — | US | claimed |
| US-20230323168-A1 | CATECHOL MODIFIERS FOR EPOXY ADHESIVES | ZYMERGEN INC. | 2023-10-12 | — | — | US | claimed |
| WO-2023003641-A2 | METHODS AND COMPOSITIONS RELATED TO A MODIFIED METHYLTRANSFERASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-26 | — | — | WO | claimed |
| EP-1809283-A2 | MORPHINE AND MORPHINE PRECURSORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-07-25 | — | — | EP | claimed |
| US-20070134169-A1 | Methods for smoking cessation or alcohol cessation or other addiction cessation | BIOGENESYS, INC. | 2007-06-14 | — | — | US | claimed |
| US-7135497-B1 | Spinal administration of at least one beta 2 adrenergic agonist such as clenbuterol and salbutamol; neurodegenerative diseases; improved locomotor function and neuromuscular strength | NEW YORK MEDICAL COLLEGE (US) | 2006-11-14 | — | — | US | claimed |
| US-20060088607-A1 | Nutritional supplement compositions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| WO-2006039691-A2 | MORPHINE AND MORPHINE PRECURSORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-04-13 | — | — | WO | claimed |
| EP-1435930-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-07-14 | — | — | EP | claimed |
| WO-2003032969-A2 | ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-04-24 | — | — | WO | claimed |
| WO-2002003918-A2 | TREATING NEURAL CONDITIONS RESULTING FROM SPINAL CORD CONTUSIONS AND OTHER CAUSES | NEW YORK MEDICAL COLLEGE (US) | 2002-01-17 | — | — | WO | claimed |
| US-6015837-A | Method for treating scoliosis with β2-adrenoceptor agonists | NEW YORK MEDICAL COLLEGE (US) | 2000-01-18 | — | — | US | claimed |
| WO-1999009966-A1 | USE OF BETA2-ADRENOCEPTOR AGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF SCOLIOSIS | NEW YORK MEDICAL COLLEGE (US) | 1999-03-04 | — | — | WO | claimed |